Geode Capital Management’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-453,952
| Closed | -$21.7M | – | 4557 |
|
|
2025
Q3 | $21.7M | Sell |
453,952
-13,135
| -3% | -$364K | ﹤0.01% | 1961 |
|
|
2025
Q2 | $7.47M | Sell |
467,087
-29,033
| -6% | -$470K | ﹤0.01% | 2529 |
|
|
2025
Q1 | $7.55M | Buy |
496,120
+14,511
| +3% | +$233K | ﹤0.01% | 2451 |
|
|
2024
Q4 | $9.77M | Sell |
481,609
-469
| -0.1% | -$11.8K | ﹤0.01% | 2395 |
|
|
2024
Q3 | $12.4M | Buy |
482,078
+29,005
| +6% | +$484K | ﹤0.01% | 2253 |
|
|
2024
Q2 | $5.83M | Buy |
453,073
+279,196
| +161% | +$4.49M | ﹤0.01% | 2642 |
|
|
2024
Q1 | $3.98M | Buy |
173,877
+57,848
| +50% | +$2.04M | ﹤0.01% | 2819 |
|
|
2023
Q4 | $3.04M | Buy |
116,029
+95,448
| +464% | +$1.91M | ﹤0.01% | 2943 |
|
|
2023
Q3 | $578K | Sell |
20,581
-229
| -1% | -$6.7K | ﹤0.01% | 3541 |
|
|
2023
Q2 | $633K | Sell |
20,810
-20,001
| -49% | -$511K | ﹤0.01% | 3551 |
|
|
2023
Q1 | $767K | Buy |
40,811
+4,019
| +11% | +$66.3K | ﹤0.01% | 3469 |
|
|
2022
Q4 | $375K | Sell |
36,792
-553
| -1% | -$8.89K | ﹤0.01% | 3812 |
|
|
2022
Q3 | $982K | Buy |
37,345
+9,710
| +35% | +$354K | ﹤0.01% | 3400 |
|
|
2022
Q2 | $1.25M | Buy |
27,635
+549
| +2% | +$43.3K | ﹤0.01% | 3317 |
|
|
2022
Q1 | $2.67M | Buy |
27,086
+2,504
| +10% | +$234K | ﹤0.01% | 3107 |
|
|
2021
Q4 | $3.76M | Buy |
24,582
+7,448
| +43% | +$1.1M | ﹤0.01% | 3047 |
|
|
2021
Q3 | $2.32M | Buy |
17,134
+1,728
| +11% | +$237K | ﹤0.01% | 3285 |
|
|
2021
Q2 | $2.26M | Buy |
+15,406
| New | +$2.36M | ﹤0.01% | 3231 |
|
Geode Capital Management's TRML Position: Q4 2025 in Review
Geode Capital Management sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 453,952 shares — an estimated $21.7M sold.
Geode Capital Management first reported a position in TRML in Q2 2021 and held it in 18 quarters. The position peaked at $21.7M in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.
- Geode Capital Management reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
- Geode Capital Management sold 453,952 Tourmaline Bio shares in Q4 2025, an estimated $21.7M.
- Geode Capital Management first reported a position in Tourmaline Bio in Q2 2021 and held it in 18 quarters.
- Geode Capital Management's Tourmaline Bio position peaked at $21.7M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.
Based on Geode Capital Management's 13F filing for Q4 2025, filed 9 Feb 2026.